Australian Clinical Labs Limited (ASX:ACL)

Market Cap	521.15M -22.7%
Revenue (ttm)	741.27M +6.4%
Net Income	32.43M +35.5%
EPS	0.17 +42.1%
Shares Out	190.90M
PE Ratio	16.01
Forward PE	14.63
Dividend	0.13 (4.66%)
Ex-Dividend Date	Sep 1, 2025

Volume	233,990
Average Volume	542,845
Open	2.720
Previous Close	2.680
Day's Range	2.690 - 2.750
52-Week Range	2.380 - 3.800
Beta	1.01
RSI	53.12
Earnings Date	Feb 16, 2026

About Australian Clinical Labs

Australian Clinical Labs Limited provides pathology diagnostic services in Australia. The company offers range of services, including molecular cancer, harmony NIPT, genetic carrier screening and other antenatal, cardiac, and commercial drug and alcohol testing services; chemical pathology, haematology, histopathology and cytopathology, serology and microbiology, allergy and immunology, and veterinary and functional pathology services; pathology services for clinical trials; and CPD programs. It serves doctors, patients, and corporate clients. ...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2020
• Employees: 4,700
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: ACL

Financial Performance

In fiscal year 2025, Australian Clinical Labs's revenue was 741.27 million, an increase of 6.45% compared to the previous year's 696.37 million. Earnings were 32.43 million, an increase of 35.50%.